Krystal Biotech, Inc. Common Stock (KRYS) is a publicly traded Healthcare sector company. As of July 5, 2026, KRYS trades at $375.07 with a market cap of $11.06B and a P/E ratio of 48.40. KRYS moved +0.85% today. Year to date, KRYS is +51.31%; over the trailing twelve months it is +165.35%. Its 52-week range spans $122.80 to $382.54. Analyst consensus is strong buy with an average price target of $340.50. Rallies surfaces KRYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
9 analysts cover KRYS: 0 strong buy, 9 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $340.50.
| Metric | Value |
|---|---|
| Price | $375.07 |
| Market Cap | $11.06B |
| P/E Ratio | 48.40 |
| EPS | $7.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $382.54 |
| 52-Week Low | $122.80 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $417.30M |
| Net Income | $225.03M |
| Gross Margin | 0.00% |
9 analysts cover KRYS: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $340.50.